Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00333190 | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER |
| 1 |
| Mar 7, 2012 |
| clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00493181 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01374139 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | completed | Phase 1 | 88 | PfizerINDUSTRY | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00763763 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive(AFR07) | completed | Phase 2 | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 5, 2011 | clinicaltrials |
| NCT00101595 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Bristol-Myers SquibbINDUSTRY | 20 | Apr 14, 2011 | clinicaltrials |
| NCT01114087 | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility(GLIFERTI) | completed | N/A | 2 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00482703 | A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | completed | Phase 1 / Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 17, 2010 | clinicaltrials |
| NCT00101816 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | completed | Phase 2 | 124 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 10, 2010 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00257647 | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) | completed | — | 25 | Hadassah Medical OrganizationOTHER | 1 | Feb 18, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00001144 | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 7, 2008 | clinicaltrials |
| NCT00001432 | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | completed | — | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00514488 | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)(CML022) | completed | Phase 3 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00514969 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase(CML003) | completed | Phase 2 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00511303 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | completed | Phase 2 | 200 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00219752 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years | completed | Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Dec 22, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 16, 2012source: clinicaltrials